Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yim H.J. | - |
dc.date.available | 2020-11-02T13:43:17Z | - |
dc.date.created | 2020-10-19 | - |
dc.date.issued | 2016-06 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/7039 | - |
dc.description.abstract | [No abstract available] | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.title | Is the tenofovir based therapy almighty for previous treatment failure in chronic hepatitis B? | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yim H.J. | - |
dc.identifier.doi | 10.3350/cmh.2016.0103 | - |
dc.identifier.scopusid | 2-s2.0-85050577301 | - |
dc.identifier.wosid | 000407831500004 | - |
dc.identifier.bibliographicCitation | Clinical and molecular hepatology, v.22, no.2, pp.238 - 240 | - |
dc.relation.isPartOf | Clinical and molecular hepatology | - |
dc.citation.title | Clinical and molecular hepatology | - |
dc.citation.volume | 22 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 238 | - |
dc.citation.endPage | 240 | - |
dc.type.rims | ART | - |
dc.type.docType | Note | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | adenine | - |
dc.subject.keywordPlus | antivirus agent | - |
dc.subject.keywordPlus | hepatitis B(e) antigen | - |
dc.subject.keywordPlus | lamivudine | - |
dc.subject.keywordPlus | phosphonic acid derivative | - |
dc.subject.keywordPlus | tenofovir | - |
dc.subject.keywordPlus | virus DNA | - |
dc.subject.keywordPlus | genetics | - |
dc.subject.keywordPlus | Hepatitis B virus | - |
dc.subject.keywordPlus | Hepatitis B, Chronic | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | treatment failure | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | Adenine | - |
dc.subject.keywordPlus | Antiviral Agents | - |
dc.subject.keywordPlus | DNA, Viral | - |
dc.subject.keywordPlus | Hepatitis B e Antigens | - |
dc.subject.keywordPlus | Hepatitis B virus | - |
dc.subject.keywordPlus | Hepatitis B, Chronic | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Lamivudine | - |
dc.subject.keywordPlus | Organophosphonates | - |
dc.subject.keywordPlus | Tenofovir | - |
dc.subject.keywordPlus | Treatment Failure | - |
dc.subject.keywordPlus | Treatment Outcome | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | Resistance | - |
dc.subject.keywordAuthor | Suboptimal | - |
dc.subject.keywordAuthor | Tenofovir | - |
dc.subject.keywordAuthor | Treatment failure | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841) 82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.